V Square Quantitative Management LLC Makes New Investment in Intuitive Surgical, Inc. $ISRG

V Square Quantitative Management LLC bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 4,443 shares of the medical equipment provider’s stock, valued at approximately $2,516,000.

Other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Intuitive Surgical by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock worth $15,026,776,000 after buying an additional 263,828 shares during the period. Capital World Investors boosted its stake in Intuitive Surgical by 1.5% in the third quarter. Capital World Investors now owns 7,728,492 shares of the medical equipment provider’s stock valued at $3,456,223,000 after acquiring an additional 116,034 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Intuitive Surgical by 1.1% during the 3rd quarter. Fisher Asset Management LLC now owns 3,889,439 shares of the medical equipment provider’s stock worth $1,739,475,000 after acquiring an additional 40,702 shares during the period. Amundi grew its holdings in Intuitive Surgical by 29.7% during the 3rd quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock worth $1,451,362,000 after acquiring an additional 739,444 shares during the period. Finally, Legal & General Group Plc raised its position in shares of Intuitive Surgical by 6.3% during the 3rd quarter. Legal & General Group Plc now owns 2,376,714 shares of the medical equipment provider’s stock valued at $1,062,938,000 after acquiring an additional 141,357 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $462.28 on Thursday. Intuitive Surgical, Inc. has a one year low of $427.84 and a one year high of $603.88. The firm has a market cap of $164.17 billion, a P/E ratio of 58.59, a P/E/G ratio of 3.49 and a beta of 1.68. The stock’s 50-day moving average is $483.27 and its 200-day moving average is $514.06.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm had revenue of $2.87 billion for the quarter, compared to analyst estimates of $2.72 billion. During the same quarter in the previous year, the firm posted $2.21 earnings per share. The business’s revenue was up 18.8% on a year-over-year basis. Equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Insider Activity

In related news, SVP Mark Brosius sold 2,362 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $498.68, for a total transaction of $1,177,882.16. Following the completion of the transaction, the senior vice president directly owned 3,554 shares in the company, valued at approximately $1,772,308.72. This trade represents a 39.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 421 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $494.96, for a total value of $208,378.16. Following the completion of the sale, the executive vice president directly owned 409 shares in the company, valued at approximately $202,438.64. This represents a 50.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 32,943 shares of company stock worth $17,279,568. 0.60% of the stock is currently owned by insiders.

Intuitive Surgical News Roundup

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Stock advanced in the latest session, signaling short-term buying interest that reflects optimism about the company’s growth prospects. Intuitive Surgical, Inc. (ISRG) Advances But Underperforms Market: Key Facts
• Positive Sentiment: Coverage highlighting Intuitive’s AI push into surgical systems reinforces the long-term growth story (potential to improve outcomes, maintain da Vinci franchise leadership). This helps justify investor appetite despite near-term valuation questions. Intuitive Surgical’s AI Push Tests Valuation And Da Vinci Growth Story
• Positive Sentiment: Analyst/features pieces pointing to large new addressable markets (e.g., anti?obesity procedures) and Intuitive’s strong balance-sheet position support a bullish multi?year case. Intuitive Surgical Stock: The Dark Horse in the Massive Anti-Obesity Market
• Positive Sentiment: Coverage noting the company’s financial strength (low/no debt, strong margins) supports investor confidence in executing product and software roadmaps. This Healthcare Stock Has No Debt and a Near-Monopoly in Its Market
• Neutral Sentiment: Erste Group made very small trims to FY2026 and FY2027 EPS estimates (FY26: $8.21 from $8.22; FY27: $9.52 from $9.54). The moves are minor but signal cautious modeling around near-term execution/visibility.
• Negative Sentiment: Goldman Sachs cut its price target from $714 to $609 but kept a Buy rating — a material reduction in upside that could pressure sentiment despite the maintained positive view. Goldman Sachs Adjusts Price Target on Intuitive Surgical to $609 from $714; Maintains Buy
• Negative Sentiment: Evercore published a pessimistic forecast for ISRG, adding near-term downside risk from an influential sell?side voice. Evercore Issues Pessimistic Forecast for Intuitive Surgical (NASDAQ:ISRG) Stock Price

Wall Street Analyst Weigh In

ISRG has been the topic of several recent research reports. Zacks Research lowered Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Robert W. Baird cut their target price on Intuitive Surgical from $655.00 to $645.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Royal Bank Of Canada boosted their target price on Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and issued a $616.00 price target on shares of Intuitive Surgical in a research report on Friday, January 23rd. Finally, Wells Fargo & Company upped their target price on shares of Intuitive Surgical from $600.00 to $654.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $607.00.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.